Evidence map›Paper›PMID 42417250›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform.

Xiaobo Dang, Chenyang Zhang, Jinlong Shang, Zongtao Zhao, Chao Wang, Zhaoqing Xu

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaobo DangKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Chenyang ZhangKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Jinlong ShangKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Zongtao ZhaoKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Chao WangKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.ORCID 0000-0002-9238-6582
Zhaoqing XuKey Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

Funding

Fundamental Research Funds for the Central Universities lzujbky-2025-it30Gansu Provincial Science and Technology Leading Talents Program 24RCKB005Key R&D Project of Gansu Province 25YFWA006National Natural Science Foundation of China 22271126National Natural Science Foundation of China 224B2703National Natural Science Foundation of China U23A20524Natural Science Foundation of Gansu Province 25JRRA726
6 · The paper itself

Abstract

Site-selective Cys bioconjugation is central to chemical biology and therapeutic development. Owing to the widespread availability of amine-containing building blocks, the modular assembly of alkylamines and Cys holds significant promise for diverse applications. However, existing strategies often suffer from reversible linkages, stereochemical heterogeneity, or limited modularity. Here we report a programmable pyridine-based chemoselective sequential conjugation platform that integrates a thianthrenium leaving group and a fluorine handle on a single pyridine scaffold, enabling sequential, orthogonal coupling of alkylamines and Cys to form non-chiral, stable aryl-Cys linkages. The reaction exhibits exceptional functional group compatibility and high chemoselectivity in both the alkylamine- and thiol-conjugation steps. The platform supports late-stage peptide diversification and stapling, protein functionalization, and streamlined construction of a HER2-targeting ADC (MRG002) analog with a tunable drug-to-antibody ratio. The resulting ADC shows slightly enhanced cytotoxicity in HER2-positive cells, comparable activity in antigen-negative controls, and markedly improved payload retention in human serum.

Indexed as

ImmunoconjugatesPyridinesCell Line, TumorCysteineErb-b2 Receptor Tyrosine KinasesHumansMolecular StructureCysteineErb-b2 Receptor Tyrosine KinasesImmunoconjugatespyridinePyridinesantibody‐drug conjugates (ADCs)cysteine modificationsequential conjugation platformsite‐selective bioconjugationstable S‐aryl linkage

Identifiers

PMID42417250
PMCPMC13573079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.